Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the clinical pregnancy rate per embryo transfer in oocytes recipients obtained after ovarian stimulation during the luteal phase of oocytes donors . This study will be performed in egg recipients and donors but this type of treatment is meant to be implemented in fertility preservation patients

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Luteal Phase-start Ovarian Stimulation With Corifollitropin Alfa

NCT03555942

Infertility

COMPLETED NA

Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation

NCT03300960

Infertility

COMPLETED PHASE3

A Comparative Study of Two Patterns of Controlled Ovarian Hyperstimulation in Mid Follicular Phase or Early Luteal Phase for Egg Donors

NCT01385332

Stimulation in the Ovary

COMPLETED NA

GnRH Agonist and Antagonists in an Oocyte Donation Program

NCT00505817

Effect of Two Protocols of Ovarian Stimulation on Oocyte Quality

COMPLETED PHASE4

Luteal Phase FSH in the IVF Poor Responder

NCT00225433

Infertility

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

INFERTILITY Fertility Preservation Ovulation Induction Vitrification Oocyte Donation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lutheal phase ovarian stimulation

Early luteal phase Controlled ovarian hyperstimulation: we will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix to induce luteolysis and FSHr (dose according to BMI and AFC )IU/day for controlled ovarian hyperstimulation until achieving criteria for hCG , to induce final oocyte maturation. Mature oocytes will be vitrified. After warming, oocytes will be inseminated by ICSI with the recipients partners semen sample . Recipient endometrium will be primed with estrogen and progesterone , and embryo transfer will be performed on the 3rd day 3 of embryo cleavage.

Group Type EXPERIMENTAL

gonadotropins plus GnRH antagonists

Intervention Type DRUG

ganirelix

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

gonadotropins plus GnRH antagonists

Intervention Type DRUG

ganirelix

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ovarian stimulation the investigators will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* premenopausal women, 18-35 years old, FSH levels \< 10 mIU/ml; AFC\> 10
* regular cycles
* BMI \< 28
* signed informed consent

Recipients:

* Infertile women eligible for oocytes donation
* BMI \< 35
* Signed informed consent form